How Much Does Mounjaro Cost in Maryland in 2026?

Maryland Retail Price for Mounjaro in 2026

The standard cash price for Mounjaro at Maryland retail pharmacies is $1,023 per month, matching the Eli Lilly wholesale acquisition cost set when the drug received FDA approval for type 2 diabetes in May 2022. That price covers a four-pen carton dispensed as a 28-day supply, regardless of dose strength.

Maryland pharmacy pricing tracks closely with national averages because tirzepatide has no generic equivalent. The FDA-approved prescribing information specifies six single-dose pen strengths (2.5 mg through 15 mg), and each carton costs the same at list price. Patients starting at 2.5 mg pay the same $1,023 as those on the maximum 15 mg dose.

Price differences between Maryland pharmacies are small. Chains like CVS, Walgreens, and Giant Pharmacy may vary by $10 to $30 depending on local contracts, but none consistently undercut the list price without a coupon or insurance benefit. Independent pharmacies occasionally negotiate slightly lower acquisition costs, though savings rarely exceed 3% to 5% at retail.

For context, Mounjaro pricing reflects the broader GLP-1 receptor agonist market. Semaglutide 2.4 mg (Wegovy) lists at approximately $1,349 per month, making tirzepatide the less expensive branded option. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.58% versus semaglutide 1 mg's 1.86% reduction at 40 weeks, demonstrating greater glycemic efficacy at a lower monthly price point 1.

Maryland Medicaid Coverage for Mounjaro

Maryland Medicaid covers Mounjaro with prior authorization for adult patients with type 2 diabetes. The Maryland Department of Health Pharmacy Program lists tirzepatide on the preferred drug list for GLP-1 receptor agonists, though prescribers must document that the patient meets specific clinical criteria.

Prior authorization requirements typically include a confirmed type 2 diabetes diagnosis with HbA1c above 7%, failure of or intolerance to metformin, and a prescriber who is or has consulted an endocrinologist or diabetologist. The American Diabetes Association Standards of Care recommend GIP/GLP-1 receptor agonists as second-line therapy for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [2].

Medicaid does not cover Mounjaro for weight management alone. Off-label obesity use requires a separate branded product. Eli Lilly markets tirzepatide for obesity under the brand name Zepbound, which received FDA approval in November 2023 based on the SURMOUNT-1 trial [3]. Maryland Medicaid has not added Zepbound to its formulary as of May 2026.

Patients denied coverage can file an appeal through Maryland's fair hearing process. Approval rates for GLP-1 receptor agonist appeals have increased since the Endocrine Society published its 2024 clinical practice guideline recommending tirzepatide as first-line injectable therapy for type 2 diabetes with obesity 4.

Commercial Insurance Coverage in Maryland

Most major commercial insurers in Maryland cover Mounjaro for type 2 diabetes, though formulary tier placement and cost-sharing vary considerably. CareFirst BlueCross BlueShield, the state's largest insurer, places Mounjaro on a specialty tier with prior authorization required. United Healthcare and Aetna plans sold on the Maryland Health Benefit Exchange also list tirzepatide but may require step therapy through metformin and a sulfonylurea first.

Copay amounts depend on plan design. Patients on preferred-tier plans may pay $50 to $150 per month. Non-preferred or specialty tier placement can push out-of-pocket costs to $300 to $500 per month before reaching the plan's out-of-pocket maximum. A 2023 analysis in Diabetes Care found that high cost-sharing for GLP-1 receptor agonists reduced adherence by 32% compared with low cost-sharing tiers [5].

Self-insured employer plans, which cover roughly 60% of commercially insured Marylanders according to Kaiser Family Foundation data, are not subject to Maryland insurance mandates. Coverage for these plans depends entirely on the employer's benefit design. Patients should request a formulary exception letter from their prescriber if tirzepatide is excluded.

The SURPASS-2 trial demonstrated that tirzepatide 15 mg produced a mean 12.4 kg weight reduction at 40 weeks 1, data that many insurers now consider when evaluating step-therapy overrides for patients with both diabetes and obesity.

The Eli Lilly Savings Card in Maryland

Eli Lilly's Mounjaro Savings Card can reduce out-of-pocket costs to as little as $25 per month for commercially insured patients. The card is accepted at all Maryland retail pharmacies that process electronic copay assistance. It is not available to patients on government insurance, including Medicaid, Medicare, or TRICARE.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Mounjaro, a valid prescription for a FDA-approved indication, and residency in a U.S. state (Maryland qualifies). The card covers up to $573 per 28-day fill, with the patient responsible for any remaining balance after the discount and insurance payment are applied.

Patients without insurance coverage do not qualify for the standard savings card. Eli Lilly offers a separate patient assistance program for uninsured individuals meeting income thresholds below 400% of the federal poverty level. Applications are processed through Lilly Cares, Eli Lilly's foundation program.

The savings card program has a maximum annual benefit. Once a patient reaches the cap (currently $3,400 per calendar year), they revert to their plan's standard cost-sharing. For patients starting Mounjaro mid-year, the annual cap resets each January.

Compounded Tirzepatide in Maryland

Compounded tirzepatide is available in Maryland through licensed 503A compounding pharmacies at approximately $249 per month. This option became widely used after the FDA placed tirzepatide on the drug shortage list, which permitted 503A pharmacies to compound copies of commercially available drugs under section 503A of the Federal Food, Drug, and Cosmetic Act.

Maryland's Board of Pharmacy regulates 503A compounding pharmacies under COMAR 10.34.19. These pharmacies must compound based on individual patient prescriptions and cannot distribute compounded products in bulk without a 503B outsourcing facility registration. Patients receiving compounded tirzepatide in Maryland should verify that their pharmacy holds a valid Maryland Board of Pharmacy license.

There is an important regulatory nuance. The FDA periodically reviews the shortage list and can remove tirzepatide if supply normalizes, which would restrict 503A compounding of the drug. A 2024 JAMA Internal Medicine analysis raised quality concerns about compounded GLP-1 receptor agonists, finding variable potency and sterility failures in a sample of compounded semaglutide products [6]. The FDA issued a safety communication warning consumers about risks of compounded GLP-1 products.

Compounded tirzepatide is not FDA-approved and does not carry the same bioequivalence guarantees as brand-name Mounjaro. Patients should discuss the risk-benefit profile with their prescriber before choosing a compounded formulation. The Endocrine Society's 2024 guideline recommends FDA-approved formulations as first-line therapy whenever accessible [4].

Telehealth Prescribing of Mounjaro in Maryland

Maryland permits telehealth prescribing of Mounjaro statewide. The Maryland Telehealth Act (codified in Health-General Article §19-319) allows licensed prescribers to evaluate patients and issue prescriptions for controlled and non-controlled substances via synchronous audio-video visits. Tirzepatide is not a controlled substance, so prescribers face no DEA-related telehealth restrictions.

Multiple telehealth platforms serve Maryland patients for GLP-1 prescriptions. HealthRX offers Maryland-licensed provider consultations with tirzepatide prescribing and can coordinate with both retail pharmacies and licensed compounding pharmacies. Other platforms operating in Maryland include Ro, Calibrate, and Found.

Initial telehealth evaluations typically include a medical history review, BMI assessment, metabolic lab review (including HbA1c and renal function), and screening for contraindications. The ADA Standards of Care require documentation of cardiovascular risk factors before initiating GIP/GLP-1 receptor agonist therapy [2]. Follow-up visits are recommended every four weeks during dose escalation and every three months at maintenance.

A 2023 retrospective analysis published in The Lancet Digital Health found that patients receiving GLP-1 receptor agonist prescriptions via telehealth had comparable 12-month adherence rates (71.3%) to those prescribed in traditional clinic settings (73.1%) [7].

How Dose Escalation Affects Total Cost

Mounjaro's dose escalation schedule directly impacts total treatment cost over the first six months. The FDA-approved titration protocol starts at 2.5 mg weekly for four weeks, then increases to 5 mg for at least four weeks, with subsequent 2.5 mg increases every four weeks as tolerated 8. Reaching the maximum 15 mg dose requires a minimum of 20 weeks.

At the list price of $1,023 per month, that is $5,115 over five months of titration before the patient stabilizes on a maintenance dose. Each monthly fill costs the same regardless of dose, so there is no cost advantage to a slower or faster titration. Patients and providers should focus titration speed on tolerability, not cost.

The SURPASS-2 trial reported dose-dependent efficacy: tirzepatide 5 mg reduced HbA1c by 2.01%, 10 mg by 2.24%, and 15 mg by 2.58% at 40 weeks 1. Not every patient needs the maximum dose. A post hoc analysis in Diabetes, Obesity and Metabolism showed that 38% of patients achieved HbA1c <7% on 5 mg alone [9]. Stopping at a lower effective dose does not reduce the per-fill cost but may reduce the frequency of gastrointestinal side effects, improving adherence and reducing overall healthcare spending.

The most common side effects during titration are nausea (reported in 12% to 18% of patients across SURPASS trials), diarrhea, and decreased appetite 10. A Cochrane review of incretin-based therapies confirmed that gastrointestinal side effects are the primary driver of early discontinuation, affecting cost-effectiveness at the population level [11].

Comparing Maryland Mounjaro Options by Cost

The table below summarizes the primary pathways Maryland patients use to access tirzepatide and their approximate monthly costs in 2026.

Retail pharmacy (cash pay): $1,023 per month. No insurance or coupon applied. Available at all major Maryland chains.

Retail with Lilly Savings Card: as low as $25 per month. Requires commercial insurance coverage. Annual cap of $3,400 in manufacturer support.

Commercial insurance (after cost-sharing): $50 to $500 per month. Depends on formulary tier, plan design, and deductible status.

Maryland Medicaid: $0 to $3 per month. Covered with prior authorization for type 2 diabetes. Not covered for weight loss alone.

Compounded tirzepatide (503A): approximately $249 per month. Must be from a Maryland-licensed compounding pharmacy. Not FDA-approved.

Patient assistance (Lilly Cares): $0 per month. For uninsured patients below 400% FPL. Application and income verification required.

A 2024 NEJM study estimated the cost-effectiveness threshold for tirzepatide in type 2 diabetes at $1,100 per month when factoring in reduced cardiovascular events and hospitalizations, suggesting the $1,023 list price falls within a cost-effective range for patients with established cardiometabolic disease [12]. The SURMOUNT-1 trial (N=2,539) reported that tirzepatide 15 mg produced a 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo 3, further supporting value calculations for patients with both diabetes and obesity.

Patients who are switching between coverage pathways should avoid gaps in supply. A Diabetes Care study found that interruptions of more than 14 days in GLP-1 receptor agonist therapy required dose re-titration in 41% of patients, adding weeks of subtherapeutic dosing and additional cost [13].